Skip to main content

Table 6 Microbiological success rates in microbiologically evaluable patients

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

  Infusion group, n (%) Bolus group, n (%) P- value
Eradication overall 87/96 (90.6%) 80/102 (78.4%) 0.020
   Verified eradication 67/96 (69.8%) 62/102 (60.8%) 0.233
   Presumed eradication 20/96 (20.8%) 18/102 (17.6%) 0.592
Culture-based therapy 82/90 (91.1%) 74/95 (77.9%) 0.015
Empiric therapy 5/6 (83.0%) 5/7 (71.4%) 1.000
Without concomitant ATB therapy potentially active against GNB 77/85 (90.6%) 75 (78.1%) 0.026
APACHE II > 20 41/47 (87.2%) 36/49 (73.5%) 0.125
MIC ≥ 1.5 mg/l 11/14 (78.6%) 13/21 (61.9%) 0.292
   Acinetobacter spp. 7/8 (87.5%) 9/12 (75%) 0.619
   Citrobacter spp. 3/3 (100%) 3/4 (75%) 1.000
   Enterobacter spp. 3/3 (100%) 7/7 (100%) n/a
   Escherichia coli 5/6 (83.3%) 7/9 (77.7%) 1.000
   Klebsiella spp. 58/63 (92.1%) 39/50 (78.0%) 0.055
   Morganella morganii 3/3 (100%) 5/5 (100%) n/a
   Pseudomonas aeruginosa 3/4 (75%) 3/6 (50%) 0.571
   Serratia marcescens 4/4 (100%) 6/6 (100%) n/a
   Stenotrophomonas maltophilia 1/2 (50%) 1/3 (33.3%) 1.000
Persistence overall 9/96 (9.4%) 22/102 (21.6%) 0.020
   Acinetobacter spp. 0/8 (0%) 2/12 (16.7%) 0,495
   Citrobacter spp. 0/3 (0%) 1/4 (25.0%) 1.000
   Escherichia coli 1/6 (16.7%) 2/9 (22.2%) 1.000
   Klebsiella spp. 5/63 (7.9%) 11/50 (22.0%) 0.055
   Pseudomonas aeruginosa 0/4 (0%) 2/6 (33.3%) 0.491
   Stenotrophomonas maltophilia 1/2 (50.0%) 0/3 (0%) 0.400
Resistance 2/96 (2.1%) 4/102 (3.9%) 0.684
   Acinetobacter spp. 1/8 (12.5%) 1/12 (8.3%) 1.000
   Pseudomonas aeruginosa 1/4 (25.0%) 1/6 (16.7%) 1.000
   Stenotrophomonas maltophilia 0/2 (0%) 2/6 (33.3%) 1.000
  1. Values are presented as absolute (percentage). APACHE II, Acute Physiology and Chronic Health Evaluation II; ATB, antibiotic; GNB, Gram-negative bacteria;
  2. MIC, minimum inhibitory concentration